BROADLY CROSS-REACTIVE MONOCLONAL ANTIBODIES AGAINST HA2 GLYCOPEPTIDE OF INFLUENZA A VIRUS HEMAGGLUTININ OF H3 SUBTYPE REDUCE REPLICATION OF INFLUENZA A VIRUSES OF HUMAN AND AVIAN ORIGIN

被引：22

作者：

Stropkovska, A. ^{[1
]}

Mucha, V. ^{[1
]}

Fislova, T. ^{[1
]}

Gocnik, M. ^{[1
]}

Kostolansky, F. ^{[1
]}

Vareckova, E. ^{[1
]}

机构：

[1] Slovak Acad Sci, Inst Virol, Bratislava 84505, Slovakia

来源：

ACTA VIROLOGICA | 2009年 / 53卷 / 01期

关键词：

influenza A virus; avian influenza; human influenza; hemagglutinin; HA2; monoclonal antibody; cross-reactivity; plaque reduction; GLYCOPOLYPEPTIDES HA1; FUSION ACTIVITY; INFECTION; VACCINE; MICE; IMMUNIZATION; INHIBITION; PROTECTION; PEPTIDE;

D O I：

10.4149/av_2009_01_15

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The reactivity of monoclonal antibodies (MAbs) prepared to the HA2 glycopeptide (gp) of A/Dunedin/4/73 (H3N2) hemagglutinin was tested against influenza A viruses of H3, H4, and H7 subtypes. Only one (CF2) out of six MAbs reacted with influenza A viruses of all three subtypes (H3, H4 and H7). The inter-subtype reactivity of this MAb (CF2) is in accord with the highly conservative sequence in the previously defined MAb-binding site 1, i.e. the aa 1-38 of N-terminus of HA2 gp. MAb CF2 as well as inter-subtype cross-reactive MAb IIF4, recognizing the binding site II of HA2 gp, were tested for their effect on replication Of influenza A viruses. Both these MAbs reduced the number of plaques of viruses of homologous (H3) as well as heterologous (H4) virus subtypes, the latter less efficiently. The potential of these MAbs to influence in vivo replication of influenza A Viruses of various subtypes is discussed.

引用

页码：15 / 20

页数：6

共 29 条

[1]

Arnon R., 2006, BTI, V18, P10

[2] Epitope-based vaccine against influenza [J].

Ben-Yedidia, Tamar ;

Arnon, Ruth .

EXPERT REVIEW OF VACCINES, 2007, 6 (06) :939-948

[3] A soluble domain of the membrane-anchoring chain of influenza virus hemagglutinin (HA(2)) folds in Escherichia coli into the low-pH-induced conformation [J].

Chen, J ;

Wharton, SA ;

Weissenhorn, W ;

Calder, LJ ;

Hughson, FM ;

Skehel, JJ ;

Wiley, DC .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (26) :12205-12209

[4]

Gerhard W, 2001, CURR TOP MICROBIOL, V260, P171

[5] Antibodies induced by the HA2 glycopolypeptide of influenza virus haemagglutinin improve recovery from influenza A virus infection [J].

Gocnik, M. ;

Fislova, T. ;

Mucha, V. ;

Sladkova, T. ;

Russ, G. ;

Kostolansky, F. ;

Vareckova, E. .

JOURNAL OF GENERAL VIROLOGY, 2008, 89 :958-967

[6] Antibodies specific to the HA2 glycopolypeptide of influenza A virus haemagglutinin with fusion-inhibition activity contribute to the protection of mice against lethal infection [J].

Gocnik, M. ;

Fislova, T. ;

Sladkova, T. ;

Mucha, V. ;

Kostolansky, F. ;

Vareckova, E. .

JOURNAL OF GENERAL VIROLOGY, 2007, 88 :951-955

[7] CHANGES IN THE INFLUENZA-VIRUS HEMAGGLUTININ AT ACID PH DETECTED BY MONOCLONAL-ANTIBODIES TO GLYCOPOLYPEPTIDES HA1 AND HA2 [J].

KOSTOLANSKY, F ;

RUSS, G ;

MUCHA, V ;

STYK, B .

ARCHIVES OF VIROLOGY, 1988, 101 (1-2) :13-24

[8]

Kostolansky F, 2002, ACTA VIROL, V46, P229

[9] Influenza: Emergence and control [J].

Lipatov, AS ;

Govorkova, EA ;

Webby, RJ ;

Ozaki, H ;

Peiris, M ;

Guan, Y ;

Poon, L ;

Webster, RG .

JOURNAL OF VIROLOGY, 2004, 78 (17) :8951-8959

[10] Vaccines for pandemic influenza [J].

Luke, CJ ;

Subbarao, K .

EMERGING INFECTIOUS DISEASES, 2006, 12 (01) :66-72

← 1 2 3 →